{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:39:56Z","timestamp":1774312796707,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jjcc.2020.08.008","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T17:30:24Z","timestamp":1600104624000},"page":"186-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Bleeding risks associated with anticoagulant therapies after percutaneous coronary intervention in Japanese patients with ischemic heart disease complicated by atrial fibrillation: A comparative study"],"prefix":"10.1016","volume":"77","author":[{"given":"Masato","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuyuki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Takita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chie","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Kogure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2020.08.008_bib0005","series-title":"Vital statistics","author":"Japan Ministry of Health, Labour and Welfare","year":"2014"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12199-018-0708-1","article-title":"Cost of illness of ischemic heart disease in Japan: a time trend and future projections","volume":"23","author":"Gochi","year":"2018","journal-title":"Environ Health Prev Med"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0015","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.je.2016.08.012","article-title":"Risk of stroke and heart failure attributable to atrial fibrillation in middle-aged and elderly people: results from a five-year prospective cohort study of Japanese community dwellers","volume":"27","author":"Ohsawa","year":"2017","journal-title":"J Epidemiol"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0020","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jjcc.2016.10.015","article-title":"Usefulness of a healthcare database for epidemiological research in atrial fibrillation","volume":"70","author":"Koretsune","year":"2017","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0025","first-page":"1426","article-title":"Antithrombotic therapy for atrial fibrillation and coronary disease demystified","volume":"34","author":"Andrade","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0030","first-page":"257","article-title":"Triple versus dual oral antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"74","author":"Dong","year":"2019","journal-title":"Pharmazie"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0035","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.carrev.2019.02.022","article-title":"Dual versus triple antithrombotic therapy in patients undergoing percutaneous coronary intervention-meta-analysis and meta-regression","volume":"20","author":"Agarwal","year":"2019","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0040","doi-asserted-by":"crossref","first-page":"837","DOI":"10.33963\/KP.14899","article-title":"Triple versus double antithrombotic therapy in patients with atrial fibrillation and stent implantation. A meta-analysis of randomized trials","volume":"77","author":"Grajek","year":"2019","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0045","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0050","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0055","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.116.025783","article-title":"Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral vitamin K antagonist treatment strategy","volume":"35","author":"Gibson","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0060","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/CIRCULATIONAHA.116.025923","article-title":"O PIONEERs! The beginning of the end of full-dose triple therapy with warfarin?","volume":"135","author":"Bhatt","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0065","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/ejcts\/ezx334","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"53","author":"Valgimigli","year":"2018","journal-title":"Eur J Cardiothoracic Surg"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0075","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/CIRCULATIONAHA.118.034722","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention","volume":"138","author":"Angiolillo","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0080","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk","volume":"40","author":"Urban","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0085","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1253\/circj.CJ-19-1109","article-title":"JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease","volume":"84","author":"Nakamura","year":"2020","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0090","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jjcc.2018.11.004","article-title":"Bleeding risk score in Japanese patients on antiplatelets plus an anticoagulant","volume":"73","author":"Fukaya","year":"2019","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0095","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jjcc.2018.10.013","article-title":"Performance of HAS-BLED, ORBIT, PRECISE-DAPT, and PARIS risk score for predicting long-term bleeding events in patients taking an oral anticoagulant undergoing percutaneous coronary intervention","volume":"73","author":"Yoshida","year":"2019","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0100","series-title":"Guidelines for the conduct of pharmacoepidemiological studies in drug safety assessment using databases of medical information","author":"Pharmaceuticals and Medical Devices Agency","year":"2014"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0105","first-page":"87","article-title":"The epidemiological study of venous thromboembolism and bleeding events using a Japanese healthcare database \u2014 validation study","volume":"17","author":"Yamaguchi","year":"2015","journal-title":"Jpn J Drug Inform"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0110","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0115","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0120","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.jacc.2018.07.054","article-title":"Combining oral anticoagulants with platelet inhibitors in patients with atrial fibrillation and coronary disease","volume":"72","author":"Sindet-Pedersen","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0125","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/CIRCULATIONAHA.118.036248","article-title":"Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy","volume":"139","author":"van Rein","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/joa3.12149","article-title":"Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): three-month interim analysis results","volume":"35","author":"Yamashita","year":"2018","journal-title":"J Arrhythm"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0135","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jjcc.2019.01.001","article-title":"Real-world outcomes of the xarelto post-authorization safety & effectiveness study in Japanese patients with atrial fibrillation (XAPASS)","volume":"74","author":"Ikeda","year":"2019","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0140","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/joa3.12184","article-title":"Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: a regulatory postmarketing surveillance, the STANDARD study","volume":"35","author":"Inoue","year":"2019","journal-title":"J Arrhythm"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0145","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.joa.2015.11.008","article-title":"Post-marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation: preliminary report of the J-dabigatran surveillance","volume":"32","author":"Inoue","year":"2016","journal-title":"J Arrhythm"},{"key":"10.1016\/j.jjcc.2020.08.008_bib0150","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/eurheartj\/ehy802","article-title":"Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials","volume":"40","author":"Wang","year":"2019","journal-title":"Eur Heart J"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508720302938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508720302938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:04:55Z","timestamp":1760274295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508720302938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0914508720302938"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2020.08.008","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bleeding risks associated with anticoagulant therapies after percutaneous coronary intervention in Japanese patients with ischemic heart disease complicated by atrial fibrillation: A comparative study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2020.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of Japanese College of Cardiology.","name":"copyright","label":"Copyright"}]}}